Insight Molecular Diagnostics Inc. (IMDX) Q3 2026 Earnings Call Transcript
What Oncocyte (IMDX) Said on Its Q3 Earnings Call
Insight Molecular Diagnostics Inc. 2026 Q3 - Results - Earnings Call Presentation
Insight Molecular Diagnostics: Q3 Earnings Snapshot
Insight Molecular Diagnostics stock tumbles on public offering
IMDx Reports Third Quarter 2026 Results and Provides Corporate Update
Insight Molecular Diagnostics Announces Proposed Public Offering
iMDx to Release Third Quarter Results on November 16, 2026
iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings
iMDx Amends Chronix Merger Agreement, Replacing Ongoing 10% CNI Monitor Royalty With 10% Sale Payment Upon CNI Monitor Sale
LUCID CAPITAL MARKETS Initiates Coverage On Insight Molecular with Buy Rating, Announces Price Target of $8
Transcript: Insight Molecular Q2 2026 Earnings Conference Call
Needham Reiterates Buy on Insight Molecular, Maintains $9 Price Target
Insight Molecular Diagnostics (IMDX) Q2 2026 Earnings Call Transcript
Oncocyte Eyes Faster, Less Invasive Heart Transplant Rejection Testing
Insight Molecular Diagnostics Inc. (IMDX) Discusses Advances in Heart Transplant Rejection Testing and Evolution of Diagnostic Methods Transcript
Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing
Insight Molecular Diagnostics To Host Virtual KOL Event On August 17 To Discuss GraftAssure Platform Leveraging Digital PCR Technology For Reliable dd-cfDNA Results In Transplanted Organ Health Monitoring
Insight Molecular Diagnostics Inc. Q2 2026 Earnings Call Summary
Insight Molecular Diagnostics Inc. (IMDX) Q2 2026 Earnings Call Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.